State of California—Health and Human Services Agency
Department of Health Care Services

JENNIFER KENT
DIRECTOR

EDMUND G. BROWN JR.
GOVERNOR

DATE: February 21, 2017

PRIME POLICY LETTER 17-004

TO: PRIME ENTITIES

SUBJECT: PRIME METRIC SPECIFICATIONS FOR DY12 MID-YEAR REPORTING

PURPOSE:

The purpose of this PRIME Policy Letter (PPL) is to inform all PRIME entities that for Demonstration Year (DY) 12 Mid-Year reporting, they have the option to use the metric specifications described in either the PRIME Reporting Manual DY 12 v1.0 (DY12 specs) or the PRIME Metric Specification Manual v2.4 (DY11 specs), with a few metric exceptions.

> ***NOTE: DMPHs engaged in infrastructure building activities and not reporting on metrics for the DY 12 Mid-Year reporting period may disregard this policy letter.***

BACKGROUND:

The DY12 specs were released to all entities participating in the PRIME Program on Friday, February 10, 2017. This manual includes the latest updates from measure stewards and incorporates the updated version of the PRIME Reporting Guide v2.3 to reflect the changes in the PRIME Reporting Platform.

DY12 mid-year reporting is scheduled to begin on March 1, 2017 and continue until March 31, 2017. The short time between the release of the DY12 specs and mid-year reporting deadlines may prove challenging for entities to reasonably implement measure specification updates.

POLICY:

For the DY12 mid-year reporting period **only**, PRIME entities are allowed to use the metric specifications described in either the DY12 specs or the DY11 specs. This choice must be reported in the second report level narrative under ‘details on reporting methods’. This choice is at the discretion of each entity and the selected version of the specifications must be applied to all metrics reported during this reporting period ***except***

for the following metrics that **REQUIRE** the use specifications described in the DY12 specs due to critical changes in clinical guidelines or reporting methods:

- 1.2.3.c & 1.6.4.c Colorectal Cancer Screening
- 1.3.3 Influenza Immunization
- 2.1.2 Exclusive Breastmilk Feeding (PC-05)
- 2.1.3 OB Hemmorage: Massive Transfusion
- 2.1.4 OB Hemmorage: Total Products Transfused
- 2.1.5 Cesarean Section (PC-02)
- 2.1.7 Severe Maternal Morbidity
- 2.1.8 Unexpected Newborn Complications

The option of choosing between two different sets of specifications is **only** for DY 12 Mid-Year reporting and will not be an option for future reporting periods.

All PRIME entities will be required to use DY12 specs during DY12 Year-End reporting.

If you have any questions regarding this PPL, please contact your PRIME Liaison or email the PRIME Mailbox at PRIME@dhcs.ca.gov.

Sincerely,

Neal D. Kohatsu, MD, MPH
Medical Director
California Department of Health Care Services